Editas Medicine, Inc. (EDIT) Expected to Post Earnings of -$0.79 Per Share

Wall Street analysts expect Editas Medicine, Inc. (NASDAQ:EDIT) to post earnings of ($0.79) per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Editas Medicine’s earnings. The lowest EPS estimate is ($1.36) and the highest is ($0.62). Editas Medicine posted earnings of ($1.10) per share during the same quarter last year, which suggests a positive year over year growth rate of 28.2%. The firm is scheduled to announce its next earnings results on Tuesday, March 6th.

According to Zacks, analysts expect that Editas Medicine will report full-year earnings of ($2.92) per share for the current fiscal year, with EPS estimates ranging from ($3.51) to ($2.74). For the next fiscal year, analysts expect that the company will post earnings of ($2.98) per share, with EPS estimates ranging from ($4.33) to ($2.23). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Editas Medicine.

Editas Medicine (NASDAQ:EDIT) last posted its earnings results on Tuesday, November 7th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.04). Editas Medicine had a negative return on equity of 70.19% and a negative net margin of 1,127.03%. The company had revenue of $6.28 million during the quarter, compared to the consensus estimate of $2.66 million. During the same period last year, the firm posted ($0.59) EPS. The company’s revenue for the quarter was up 553.0% on a year-over-year basis.

EDIT has been the subject of a number of recent research reports. ValuEngine raised shares of Editas Medicine from a “sell” rating to a “hold” rating in a research report on Saturday, September 30th. J P Morgan Chase & Co set a $27.00 price objective on shares of Editas Medicine and gave the company a “hold” rating in a research report on Wednesday, August 9th. Zacks Investment Research downgraded shares of Editas Medicine from a “buy” rating to a “hold” rating in a research report on Monday, November 13th. Cann reaffirmed a “hold” rating on shares of Editas Medicine in a report on Thursday, August 10th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Editas Medicine in a report on Tuesday, November 7th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $26.73.

In other news, CEO Katrine Bosley sold 10,000 shares of the company’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $20.42, for a total transaction of $204,200.00. Following the sale, the chief executive officer now directly owns 1,414,629 shares in the company, valued at approximately $28,886,724.18. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In the last quarter, insiders sold 43,332 shares of company stock worth $946,504. Corporate insiders own 19.40% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. IHT Wealth Management LLC purchased a new stake in shares of Editas Medicine during the 2nd quarter valued at about $107,000. Great West Life Assurance Co. Can raised its position in shares of Editas Medicine by 519.9% during the 3rd quarter. Great West Life Assurance Co. Can now owns 4,959 shares of the company’s stock valued at $114,000 after buying an additional 4,159 shares in the last quarter. Bank of America Corp DE raised its position in shares of Editas Medicine by 72.2% during the 1st quarter. Bank of America Corp DE now owns 5,936 shares of the company’s stock valued at $133,000 after buying an additional 2,489 shares in the last quarter. DekaBank Deutsche Girozentrale purchased a new stake in shares of Editas Medicine during the 2nd quarter valued at about $127,000. Finally, Legal & General Group Plc raised its position in Editas Medicine by 308.4% in the 2nd quarter. Legal & General Group Plc now owns 8,654 shares of the company’s stock worth $145,000 after purchasing an additional 6,535 shares during the period. Hedge funds and other institutional investors own 67.17% of the company’s stock.

Shares of Editas Medicine (NASDAQ EDIT) opened at $25.05 on Friday. Editas Medicine has a 1 year low of $13.12 and a 1 year high of $29.20. The company has a debt-to-equity ratio of 0.19, a quick ratio of 10.12 and a current ratio of 10.12.

TRADEMARK VIOLATION WARNING: “Editas Medicine, Inc. (EDIT) Expected to Post Earnings of -$0.79 Per Share” was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at https://ledgergazette.com/2017/11/18/editas-medicine-inc-edit-expected-to-post-earnings-of-0-79-per-share-2.html.

About Editas Medicine

Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.

Get a free copy of the Zacks research report on Editas Medicine (EDIT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply